Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT01209689
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
Phase 3
Terminated
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Drug: PlaceboBiological: tocilizumab
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 306
- Registration Number
- NCT01209702
A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Placebo - MADDrug: RO5271983 - SADDrug: Placebo - SADDrug: RO5271983 - MAD
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 82
- Registration Number
- NCT01209221
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 74
- Registration Number
- NCT01204697
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
Phase 3
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: Prednisone/Prednisolone
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 410
- Registration Number
- NCT01200758
- Locations
- 🇨🇴
Fundacion Cardioinfantil, Bogota, Colombia
🇲🇽Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre, Chihuahua, Mexico
🇨🇴Centro Medico Imbanaco, Cali, Colombia
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01201265
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Completed
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1155
- Registration Number
- NCT01200225
A Study of RO5310074 in Patients With Psoriatic Arthritis
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT01199809
A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT01197911
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT01196052
© Copyright 2025. All Rights Reserved by MedPath